Andre Moreira

Prof. Andre Moreira


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
AMAndre Moreira
Andre Moreira
POPaolo S.S. Ocampo
Paolo S.S. Ocampo
YXYuhe Xia
Yuhe Xia
HZHua Zhong
Hua Zhong
PRPrudence A. Russell
Prudence A. Russell
MMMari Mino-Kenudson
Mari Mino-Kenudson

15 April 2016 in Archives of Pathology & Laboratory Medicine
Verified
Journal Article
Open access
Sinchita Roy-ChowdhuriSinchita Roy-Chowdhuri
Sinchita Roy-Chowdhuri
DADara L. Aisner
Dara L. Aisner
TATimothy Craig Allen
Timothy Craig Allen
MBMary Beth Beasley
Mary Beth Beasley
ABAlain Borczuk
Alain Borczuk
YYYasushi Yatabe
Yasushi Yatabe
The advent of targeted therapy in lung cancer has heralded a paradigm shift in the practice of cytopathology with the need for accurately subtyping lung carcinoma, as well as providing adequate material for molecular studies, to help guide clinical and therapeutic decisions. The variety and versatility of cytologic-specimen preparations offer significant advantages to molecular testing; however, they frequently remain underused. Therefore, evaluating the utility and adequacy of cytologic specimens is critical, not only from a lung cancer diagnosis standpoint but also for the myriad ancillary studies that are necessary to provide appropriate clinical management. A large fraction of lung cancers are diagnosed by aspiration or exfoliative cytology specimens, and thus, optimizing strategies to triage and best use the tissue for diagnosis and biomarker studies forms a critical component of lung cancer management. This review focuses on the opportunities and challenges of using cytologic specimens for molecular diagnosis of lung cancer and the role of cytopathology in the molecular era.

29 July 2021 in Laboratory Investigation
Verified
Journal Article
Closed access
FZFang Zhou
Fang Zhou
JVJulian A. Villalba
Julian A. Villalba
TSTreah May S. Sayo
Treah May S. Sayo
NNNavneet Narula
Navneet Narula
HPHarvey Pass
Harvey Pass
AMAndre Moreira
Andre Moreira

1 December 2021 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
LLLawrence Hsu Lin
Lawrence Hsu Lin
DADouglas H. R. Allison
Douglas H. R. Allison
YFYang Feng
Yang Feng
GJGeorge Jour
George Jour
KPKyung Park
Kyung Park
PCPaolo Cotzia
Paolo Cotzia

26 August 2024 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
NRNatasha Rekhtman
Natasha Rekhtman
STSam E. Tischfield
Sam E. Tischfield
CAChristopher Febres Aldana
Christopher Febres Aldana
JLJake June-Koo. Lee
Jake June-Koo. Lee
JCJason C. Chang
Jason C. Chang
CRCharles M. Rudin
Charles M. Rudin
Small cell lung carcinoma (SCLC) is a highly aggressive malignancy that is typically associated with tobacco exposure and inactivation of RB1 and TP53 genes. Here, we performed detailed clinicopathologic, genomic, and transcriptomic profiling of an atypical subset of SCLC that lacked RB1 and TP53 co-inactivation and arose in never/light smokers. We found that most cases were associated with chromothripsis—massive, localized chromosome shattering—recurrently involving chromosome 11 or 12 and resulting in extrachromosomal amplification of CCND1 or co-amplification of CCND2/CDK4/MDM2, respectively. Uniquely, these clinically aggressive tumors exhibited genomic and pathologic links to pulmonary carcinoids, suggesting a previously uncharacterized mode of SCLC pathogenesis via transformation from lower-grade neuroendocrine tumors or their progenitors. Conversely, SCLC in never-smokers harboring inactivated RB1 and TP53 exhibited hallmarks of adenocarcinoma-to-SCLC derivation, supporting two distinct pathways of plasticity-mediated pathogenesis of SCLC in never-smokers. Significance: Here, we provide the first detailed description of a unique SCLC subset lacking RB1/TP53 alterations and identify extensive chromothripsis and pathogenetic links to pulmonary carcinoids as its hallmark features. This work defines atypical SCLC as a novel entity among lung cancers, highlighting its exceptional histogenesis, clinicopathologic characteristics, and therapeutic vulnerabilities. See related commentary by Nadeem and Drapkin, p. 8

23 October 2023 in Histopathology
Verified
Journal Article
Closed access
JWJonathan Willner
Jonathan Willner
NNNavneet Narula
Navneet Narula
AMAndre Moreira
Andre Moreira